Does Dr. RIHAB AHMED-TAHA have financial conflicts of interest?

Dr. RIHAB AHMED-TAHA (MD) has received a total of $979 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $979 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. RIHAB AHMED-TAHA?

According to CMS Open Payments data, Dr. RIHAB AHMED-TAHA received funding from ASTRAZENECA PHARMACEUTICALS ($205), BAYER HEALTHCARE PHARMACEUTICALS ($143), and TRAVERE THERAPEUTICS ($91).

Does Dr. RIHAB AHMED-TAHA receive research grants or speaking fees?

Dr. RIHAB AHMED-TAHA has received $979 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. RIHAB AHMED-TAHA

MDReal-Time Hydrated

Specialty: Internal Medicine, Nephrology

Practice Location: LAKEWOOD, CO 80228

NPI Number: 1518164300

LIFETIME INDUSTRY VALUE

$979

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. AHMED-TAHA is a verified Internal Medicine, Nephrology practitioner based in LAKEWOOD, CO.

Between 2021 and 2025, Dr. AHMED-TAHA had an overall industry promotional and research financial footprint of $979 as recorded in the federal CMS Open Payments database.

$979 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. AHMED-TAHA's primary funding source is ASTRAZENECA PHARMACEUTICALS, which accounts for $205 (representing 20.9% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

ASTRAZENECA PHARMACEUTICALS

Rank 1

$205

20.9%

BAYER HEALTHCARE PHARMACEUTICALS

Rank 2

$143

14.6%

TRAVERE THERAPEUTICS

Rank 3

$91

9.3%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.